Methamphetamine

Methamphetamine is a synthetic stimulant belonging to the substituted amphetamine and phenethylamine families, and it acts on the body as a sympathomimetic, mimicking the effects of the fight-or-flight system ^[1][2]. It exists as two mirror-image forms: dextromethamphetamine, the more powerful central stimulant, and levomethamphetamine, a much weaker isomer that appears in some over-the-counter nasal decongestants ^[1]. The medically and illicitly used material is usually the hydrochloride salt, which in its illegal crystalline form is known as crystal meth ^[1].

The drug was first synthesized in the late nineteenth century by the Japanese chemist Nagai Nagayoshi from the plant stimulant ephedrine, and a crystallized form was later prepared by Akira Ogata in the early twentieth century ^[1]. During the Second World War, methamphetamine was distributed widely to soldiers and workers under names such as Pervitin to combat fatigue ^[1]. It is still legally manufactured as a pharmaceutical, sold in the United States under the brand name Desoxyn, but most of the methamphetamine in circulation today is produced illicitly ^[1].

In medicine methamphetamine is a tightly restricted option for attention-deficit hyperactivity disorder and, less commonly, for short-term treatment of obesity ^[1]. Its far larger presence is as a recreational drug taken for the euphoria, alertness, and heightened energy it produces, effects that make it strongly reinforcing ^[1][2]. Repeated use readily leads to addiction, and stopping after heavy use brings on a withdrawal syndrome dominated by depressed mood, anxiety, fatigue, and disturbed sleep that can persist for weeks ^[2]. High doses can trigger a stimulant psychosis with paranoia and hallucinations, and chronic use is associated with cardiovascular damage, cognitive problems, and a raised risk of Parkinson's disease ^[2][3]. As of recent reviews, no medication has been established as an effective treatment for methamphetamine addiction, so care relies mainly on psychosocial approaches ^[1].

A major concern with methamphetamine is its neurotoxicity. Animal studies and human imaging show that repeated high doses can injure the brain's dopamine-releasing and serotonin-releasing nerve terminals, an effect linked to oxidative stress, overheating, and disturbed energy metabolism within neurons ^[3][4][5]. This dopaminergic damage underlies much of the lasting psychiatric and cognitive harm seen in long-term users ^[3][5]. Reflecting its high potential for abuse alongside a narrow accepted medical use, methamphetamine is controlled as a Schedule II substance in the United States and is similarly restricted internationally ^[1].

High-risk drug carrying an FDA boxed warning for a high potential for abuse and dependence and for sudden death and serious cardiovascular events with misuse; it must be prescribed and dispensed sparingly. Cardiovascular effects are serious, including raised heart rate and blood pressure, arrhythmias, cardiomyopathy, vasospasm, pulmonary hypertension, stroke, and sudden death, especially with pre-existing heart disease or high doses. Central effects include insomnia, anxiety, agitation, aggression and, at higher doses, stimulant psychosis with paranoia and hallucinations.

Chronic or high-dose exposure is neurotoxic to dopamine and serotonin terminals through oxidative stress and can impair mood, memory, and motor control; therapeutic low oral doses carry substantially less risk than illicit use. Appetite suppression, weight loss, and growth suppression in children occur. It is contraindicated with monoamine oxidase inhibitors, which can trigger a life-threatening hypertensive crisis, and in advanced cardiovascular disease, hyperthyroidism, glaucoma, agitation, and a history of substance abuse. Abrupt discontinuation after heavy use causes a crash with depression and fatigue, and overdose can be fatal. It must be kept secured; diversion and misuse are major hazards.

Methamphetamine has extensive labeled interactions (Desoxyn). Co-administration with monoamine oxidase inhibitors, or use within 14 days of an MAOI, is contraindicated because impaired catecholamine metabolism can precipitate hypertensive crisis. Combination with other serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, linezolid) raises the risk of serotonin syndrome, and concurrent sympathomimetics or decongestants add to cardiovascular and pressor effects. Methamphetamine also antagonizes the effect of antihypertensive agents, while urinary acidifiers increase its renal clearance and alkalinizers (including sodium bicarbonate and acetazolamide) prolong its action; it is a CYP2D6 substrate, so strong CYP2D6 inhibitors may raise exposure. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Methamphetamine was first synthesized from ephedrine in 1893 by the Japanese chemist Nagai Nagayoshi, and in 1919 his associate Akira Ogata worked out a crystallization of the compound, yielding the smokable crystalline form. The German firm Temmler brought it to market as Pervitin in 1938, and it was distributed at scale to Wehrmacht and Luftwaffe troops during the Second World War as a stimulant; comparable military stimulant use occurred in Japan and among Allied forces. In the United States it was later marketed by Abbott as the prescription product Desoxyn for narcolepsy, obesity, and attention deficit disorder, and it remains a Schedule II controlled substance. Since mid-century, clandestine manufacture has driven a large illicit market, and methamphetamine is now far more associated with that grey and illegal supply than with its narrow surviving medical use.

Methamphetamine has an almost complete split between its two identities, and the site's position is that both are real. It holds a genuine prescription indication for ADHD and for obesity, marketed as Desoxyn, and in that narrow context it is a stimulant with a long record and a defined dose. It is also one of the most damaging drugs of misuse in circulation, and the neurotoxicity, the dependence and the psychosis risk associated with high-dose non-medical use are not exaggerations.

What distinguishes it pharmacologically from other amphetamines is greater lipid solubility and therefore faster and higher central nervous system entry at equivalent dose, which is the whole basis of both its clinical potency and its misuse potential. It is not a different mechanism, it is a steeper version of the same one.

Its prescription use is now rare, and the honest reason is not that it is ineffective but that the alternatives are equally effective with a fraction of the risk and none of the handling problems. This entry exists because the compound is real and readers encounter it, not as a recommendation of any kind.